BR9815017A - Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada - Google Patents

Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada

Info

Publication number
BR9815017A
BR9815017A BR9815017-0A BR9815017A BR9815017A BR 9815017 A BR9815017 A BR 9815017A BR 9815017 A BR9815017 A BR 9815017A BR 9815017 A BR9815017 A BR 9815017A
Authority
BR
Brazil
Prior art keywords
methyl
hydrogen
alpha
halo
group
Prior art date
Application number
BR9815017-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas Lee Cupps
Sophie Lee Bogdan
Nicholas Nikolaides
Sheri Ann Gilbert
Michael Gazda
Roy Lee Martin Dobson
Charles Andrew Cruze Iii
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9815017A publication Critical patent/BR9815017A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9815017-0A 1997-11-24 1998-11-20 Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada BR9815017A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25
PCT/US1998/024694 WO1999026942A1 (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability

Publications (1)

Publication Number Publication Date
BR9815017A true BR9815017A (pt) 2001-09-11

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815017-0A BR9815017A (pt) 1997-11-24 1998-11-20 Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada

Country Status (23)

Country Link
US (1) US6486190B1 (enExample)
EP (1) EP1037887B1 (enExample)
JP (1) JP2001524478A (enExample)
KR (1) KR20010032435A (enExample)
CN (1) CN1284073A (enExample)
AT (1) ATE271048T1 (enExample)
BR (1) BR9815017A (enExample)
CA (1) CA2311344C (enExample)
CO (1) CO4970802A1 (enExample)
DE (1) DE69825075T2 (enExample)
ES (1) ES2223143T3 (enExample)
HU (1) HUP0101469A3 (enExample)
IL (1) IL136303A (enExample)
IN (1) IN190809B (enExample)
NO (1) NO20002655L (enExample)
NZ (1) NZ504707A (enExample)
PE (1) PE133699A1 (enExample)
PL (1) PL340711A1 (enExample)
RU (1) RU2193562C2 (enExample)
SK (1) SK7792000A3 (enExample)
TR (1) TR200002242T2 (enExample)
TW (1) TW505642B (enExample)
WO (1) WO1999026942A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081443A1 (en) 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
RU2225401C1 (ru) * 2002-09-16 2004-03-10 Катаев Валерий Алексеевич 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность
US20040167194A1 (en) * 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
US7268255B2 (en) * 2003-02-20 2007-09-11 Lonza Ag Process for the preparation of N-substituted formamides
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
RU2306137C1 (ru) * 2005-12-28 2007-09-20 Денис Вячеславович Лисицын Средство для профилактики и лечения гриппа
WO2013130577A2 (en) * 2012-02-27 2013-09-06 Eye Therapies, Llc Compositions and methods for the treatment of migraine
US20150133516A1 (en) * 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
WO1982000824A1 (en) 1980-09-05 1982-03-18 Geissmann F 1h and 2h indazol derivatives and medicaments containing them
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
TW300219B (enExample) * 1991-09-14 1997-03-11 Hoechst Ag
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
PL340711A1 (en) 2001-02-26
CN1284073A (zh) 2001-02-14
PE133699A1 (es) 2000-03-05
ES2223143T3 (es) 2005-02-16
CA2311344A1 (en) 1999-06-03
CO4970802A1 (es) 2000-11-07
KR20010032435A (ko) 2001-04-25
CA2311344C (en) 2006-02-07
IN190809B (enExample) 2003-08-23
HUP0101469A3 (en) 2003-01-28
IL136303A (en) 2004-02-08
HUP0101469A2 (hu) 2001-10-28
DE69825075D1 (de) 2004-08-19
DE69825075T2 (de) 2005-08-25
TR200002242T2 (tr) 2000-11-21
EP1037887B1 (en) 2004-07-14
WO1999026942A8 (en) 2000-08-03
ATE271048T1 (de) 2004-07-15
US6486190B1 (en) 2002-11-26
IL136303A0 (en) 2001-05-20
EP1037887A1 (en) 2000-09-27
JP2001524478A (ja) 2001-12-04
NO20002655D0 (no) 2000-05-24
SK7792000A3 (en) 2001-01-18
NO20002655L (no) 2000-07-24
NZ504707A (en) 2002-11-26
WO1999026942A1 (en) 1999-06-03
RU2193562C2 (ru) 2002-11-27
TW505642B (en) 2002-10-11

Similar Documents

Publication Publication Date Title
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
TR199801562T2 (xx) Viral enfeksiyonlar�n iyile�tirilmesi i�in kullan�labilecek benzimidazol i�eren bir farmas�tik bile�im.
BR1100931A (pt) Compostos derivados de aril-heteroaril carbinóis, processos para a preparação dos compostos, composições farmacêuticas, e, uso dos compostos derivados de aril-heteroaril carbinóis
KR930021637A (ko) 1,2,4-옥사디아졸릴-페녹시알킬이소옥사졸 및 항바이러스제로서의 그의 용도
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
KR960007592A (ko) 신규한 피롤로카바졸
EP0614661A3 (en) Benzylidene and cinnamylidene malononitrile derivatives to inhibit proliferative processes in mammalian cells.
NO152047C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksom 5-(paradeuterofenyl)-5-fenylhydantoin
WO1999026942A8 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
SE8304513D0 (sv) Derivatvies of omega-amino acids, the preparation and utilisation thereof, and the compositions containing these derivatives
KR890009867A (ko) 비 펩타이드성 레닌 억제제
KR910014119A (ko) 항-고혈압 활성을 갖는 티아졸리딘 유도체 및 그의 치료용도
ATE73449T1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ZA941964B (en) Substituted (arylalkylaminobezyl) aminopropionamide derivatives and process for their preparation
DK0395527T3 (da) Imidazobenzodiazepiner og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf
AU542352B2 (en) Cephalosporins
DE3481059D1 (de) Neue 11-piperazinyl-5h-imidazo(2,1-c)(1,4)benzodiazepine, verfahren zu ihrer herstellung und zwischenprodukte und erstere enthaltende arzneimittel.
PT84635A (en) Process for the preparation of stable injectable compositions containing 4-amino-5-chloro-n-]2-(diethylamino) ethyl"-2-](substituted) alkoxy" benzamide antiemetic agents
KR890011593A (ko) 쇼크 치료에 사용하기 위한 2-(페닐아미노)이미디졸린-(2)의 용도
FI933118L (fi) Oksodibentsoksepiinijohdannaiset
MX9709833A (es) Uso de benzimidazoles para la fabricacion de un medicamento para el tratamiento de leucemia.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.